Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-12-30
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00193466
Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-12-30
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00193440
OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2014-04-01
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 63
- Registration Number
- NCT00193154
- Locations
- 🇺🇸
Medical Oncology LLC, Baton Rouge, Louisiana, United States
🇺🇸Grand Rapids Oncology Program, Grand Rapids, Michigan, United States
Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory and/or Advanced Solid Tumors
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 18
- Registration Number
- NCT00193583
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2013-07-31
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 102
- Registration Number
- NCT00193037
- Locations
- 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 51
- Registration Number
- NCT00193479
- Locations
- 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 75
- Registration Number
- NCT00193427
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2015-01-05
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT00193492
- Locations
- 🇺🇸
Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
🇺🇸Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
🇺🇸Oncology Hematology Care, Cincinnati, Ohio, United States
Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2014-03-12
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 41
- Registration Number
- NCT00193063
Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT00193336
© Copyright 2024. All Rights Reserved by MedPath